109 studies found for:    NIAID | Open Studies | Exclude Unknown | Acquired Immunodeficiency Syndrome OR Human Immunodeficiency Virus OR chlamydia OR genital herpes OR gonorrhea OR pelvic inflammatory
Show Display Options
Rank Status Study
21 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
22 Recruiting Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Condition: HIV Infection
Intervention: Drug: Pegylated Interferon Alpha 2b (PEGINTRON)
23 Recruiting Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Conditions: Hepatitis;   HIV;   Liver Cancer
Intervention:
24 Not yet recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
25 Recruiting Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Efavirenz (EFV);   Drug: Rifampin-containing anti-TB therapy
26 Recruiting Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Raltegravir
27 Recruiting Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
28 Not yet recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin
29 Recruiting Safety of and Immune Response to Dolutegravir (GSK1349572) in HIV-1 Infected Infants, Children, and Adolescents
Condition: HIV Infections
Interventions: Drug: Dolutegravir (DTG) tablet formulation;   Drug: DTG oral pediatric granules taken as suspension or granules
30 Recruiting Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: SC placebo for VRC01;   Biological: IV placebo for VRC01
31 Not yet recruiting Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123;   Biological: NYVAC-HIV-PT1;   Biological: NYVAC-HIV-PT4;   Biological: AIDSVAX B/E®;   Biological: Placebo vaccine
32 Not yet recruiting Evaluating the Safety and Pharmacokinetics of VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants
Condition: HIV Infections
Intervention: Biological: VRC01
33 Recruiting Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Drug: GSK1265744 Tablets;   Drug: Injectable GSK1265744;   Drug: Placebo for GSK1265744 Tablets;   Drug: Injectable Placebo for GSK1265744
34 Recruiting Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Isoniazid (INH);   Drug: Placebo for isoniazid (INH)
35 Recruiting Evaluating the Safety and Efficacy of Single-Dose Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load
Condition: HIV Infections
Interventions: Drug: Romidepsin;   Drug: Placebo for RMD: 0.9% sodium chloride for injection
36 Not yet recruiting Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: NYVAC-HIV-PT1 vaccine;   Biological: NYVAC-HIV-PT4 vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo for DNA/NYVAC/AIDSVAX
37 Not yet recruiting Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo
38 Recruiting Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA Nat-B env;   Biological: DNA CON-S env;   Biological: DNA Mosaic env;   Biological: MVA-CMDR;   Biological: Placebo for DNA Nat-B env;   Biological: Placebo for DNA CON-S env;   Biological: Placebo for DNA Mosaic env;   Biological: Placebo for MVA-CMDR
39 Not yet recruiting Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX®-GP HIV-1 DNA vaccine;   Biological: Interleukin-12 (IL-12) DNA adjuvant;   Biological: Placebo
40 Recruiting Evaluating the Safety, Tolerance, Drug Interactions, and Effective Dosing of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in ART-Naive Children Infected With HIV and TB
Conditions: HIV Infections;   Tuberculosis
Intervention: Drug: Raltegravir

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years